News | October 09, 2025
Briefs: Panacea Biotec and Shukra Pharmaceuticals
Panacea Biotec receives acceptance from CMSS for supply of bOPV
Panacea Biotec receives acceptance from CMSS for supply of bOPV
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
New study presents a human-relevant stress model for assessing potential therapeutics
Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
Subscribe To Our Newsletter & Stay Updated
